• Je něco špatně v tomto záznamu ?

Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies

MS. Freedman, C. Pozzilli, EK. Havrdova, A. Lemle, M. Burcklen, A. Larbalestier, B. Hennessy, T. Sidorenko, A. Vaclavkova, T. Olsson, Ponesimod Phase II Study Group

. 2022 ; 99 (8) : e762-e774. [pub] 20220606

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22033334

OBJECTIVE: To evaluate the dose-response relationship of 10, 20, and 40 mg ponesimod and long-term efficacy and safety of ponesimod 20 mg using an analysis of combined data from the phase 2 Core and Extension studies in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: In the Core study, 464 patients were randomized (1:1:1:1): placebo (n = 121), 10 mg (n = 108), 20 mg (n = 116), or 40 mg ponesimod (n = 119) once daily for 24 weeks. Patients who completed the Core study transitioned into the Extension study, which had treatment period 1 (TP1; up to 96 weeks) and TP2 and TP3 (up to 432 weeks). The 40 mg dose was discontinued due to low tolerability at the end of TP1, and the 10 mg dose was subsequently discontinued due to lower benefit-risk profile vs 20 mg at the end of TP2. All patients received 10 or 20 mg during TP2, followed by 20 mg in TP3. Annualized relapse rate (ARR), 6-month confirmed disability accumulation (CDA), time to first confirmed relapse, MRI outcomes, and safety were evaluated. RESULTS: A total of 435 patients received ≥1 dose of ponesimod (first randomized dose: 10 mg = 139, 20 mg = 145, and 40 mg = 151) at any time during the Core and/or the Extension study. As of March 31, 2019, 214 patients were still on ponesimod treatment. The median (range) of ponesimod exposure was 7.95 (0-9.36) years. Ponesimod 20 mg, from Core up to the end of TP3, was associated with sustained low clinical activity (ARR for confirmed relapses: 0.154; at week 432, Kaplan-Meier estimate for confirmed relapse was 43.9%, and 6-month CDA was 20.4%) and MRI disease activity, and over 64% of patients remained free of a confirmed relapse. Most common adverse events were nasopharyngitis (30%), headache (24%), and upper respiratory tract infection (21%). CONCLUSION: The effects on multiple sclerosis disease control were maintained with ponesimod 20 mg for approximately 8 years with no new safety concerns identified. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in individuals with RRMS, long-term treatment with ponesimod 20 mg was associated with a sustained low annualized confirmed relapse rate (0.154 at week 432), with 64% of patients remaining relapse-free. TRIAL REGISTRATION INFORMATION: EudraCT Number 2008-006786-92 (Core study) and EudraCT Number 2009-011470-15 (Extension study).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033334
003      
CZ-PrNML
005      
20230131151122.0
007      
ta
008      
230120s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1212/WNL.0000000000200606 $2 doi
035    __
$a (PubMed)35667837
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Freedman, Mark S $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden. mfreedman@toh.ca $1 https://orcid.org/0000000312559701
245    10
$a Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies / $c MS. Freedman, C. Pozzilli, EK. Havrdova, A. Lemle, M. Burcklen, A. Larbalestier, B. Hennessy, T. Sidorenko, A. Vaclavkova, T. Olsson, Ponesimod Phase II Study Group
520    9_
$a OBJECTIVE: To evaluate the dose-response relationship of 10, 20, and 40 mg ponesimod and long-term efficacy and safety of ponesimod 20 mg using an analysis of combined data from the phase 2 Core and Extension studies in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: In the Core study, 464 patients were randomized (1:1:1:1): placebo (n = 121), 10 mg (n = 108), 20 mg (n = 116), or 40 mg ponesimod (n = 119) once daily for 24 weeks. Patients who completed the Core study transitioned into the Extension study, which had treatment period 1 (TP1; up to 96 weeks) and TP2 and TP3 (up to 432 weeks). The 40 mg dose was discontinued due to low tolerability at the end of TP1, and the 10 mg dose was subsequently discontinued due to lower benefit-risk profile vs 20 mg at the end of TP2. All patients received 10 or 20 mg during TP2, followed by 20 mg in TP3. Annualized relapse rate (ARR), 6-month confirmed disability accumulation (CDA), time to first confirmed relapse, MRI outcomes, and safety were evaluated. RESULTS: A total of 435 patients received ≥1 dose of ponesimod (first randomized dose: 10 mg = 139, 20 mg = 145, and 40 mg = 151) at any time during the Core and/or the Extension study. As of March 31, 2019, 214 patients were still on ponesimod treatment. The median (range) of ponesimod exposure was 7.95 (0-9.36) years. Ponesimod 20 mg, from Core up to the end of TP3, was associated with sustained low clinical activity (ARR for confirmed relapses: 0.154; at week 432, Kaplan-Meier estimate for confirmed relapse was 43.9%, and 6-month CDA was 20.4%) and MRI disease activity, and over 64% of patients remained free of a confirmed relapse. Most common adverse events were nasopharyngitis (30%), headache (24%), and upper respiratory tract infection (21%). CONCLUSION: The effects on multiple sclerosis disease control were maintained with ponesimod 20 mg for approximately 8 years with no new safety concerns identified. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in individuals with RRMS, long-term treatment with ponesimod 20 mg was associated with a sustained low annualized confirmed relapse rate (0.154 at week 432), with 64% of patients remaining relapse-free. TRIAL REGISTRATION INFORMATION: EudraCT Number 2008-006786-92 (Core study) and EudraCT Number 2009-011470-15 (Extension study).
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    12
$a roztroušená skleróza $x farmakoterapie $7 D009103
650    12
$a relabující-remitující roztroušená skleróza $x diagnostické zobrazování $x farmakoterapie $7 D020529
650    _2
$a recidiva $7 D012008
650    _2
$a thiazoly $7 D013844
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pozzilli, Carlo $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden
700    1_
$a Havrdova, Eva Kubala $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden
700    1_
$a Lemle, Alexandre $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden
700    1_
$a Burcklen, Michel $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden
700    1_
$a Larbalestier, Anna $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden
700    1_
$a Hennessy, Brian $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden
700    1_
$a Sidorenko, Tatiana $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden
700    1_
$a Vaclavkova, Andrea $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden
700    1_
$a Olsson, Tomas $u From the Multiple Sclerosis Research Unit, Department of Medicine, The University of Ottawa; The Ottawa Hospital Research Institute, Ontario, Canada (M.S.F.); Department of Human Neuroscience, Sapienza University of Rome, Italy (C.P.); Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic (E.K.H.); Actelion Pharmaceuticals Ltd, Part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Allschwil, Switzerland (A. Lemle, M.B., A. Larbalestier, B.H., T.S., A.V.); and Karolinska Institute (T.O.), Stockholm, Sweden
710    2_
$a Ponesimod Phase II Study Group
773    0_
$w MED00003491 $t Neurology $x 1526-632X $g Roč. 99, č. 8 (2022), s. e762-e774
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35667837 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151118 $b ABA008
999    __
$a ok $b bmc $g 1891871 $s 1184669
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 99 $c 8 $d e762-e774 $e 20220606 $i 1526-632X $m Neurology $n Neurology $x MED00003491
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace